Evidence map›Paper›PMID 34519775›Full record

ArticleJAMA oncology2021

Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma-Renewed Enthusiasm and a Lingering Challenge.

Laercio Lopes DaSilva, Pedro Nazareth Aguiar, Gilberto de Lima Lopes

Registry-linked trialAbstract readEditorialComment
PubMed Publisher
In one paragraph

Article in JAMA oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06863831 (Yishen Qutong Granules vs. Simulant Combined With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy in the Treatment of Locally Advanced Esophageal Cancer), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06863831 naenrolling by invitationnot on this mapstarted 2024, after this paper: background citation

Yishen Qutong Granules vs. Simulant Combined With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy in the Treatment of Locally Advanced Esophageal Cancer: A Multicenter, Prospective, Double-Blind, Randomized Controlled Trial Protocol

TypeinterventionalSponsorCancer Institute and Hospital, Chinese Academy of Medical SciencesRan2024 to 2027Enrolled536ConditionsEsophageal Squamous Cell Carcinoma (ESCC)ArmsYishen Qutong Granules, Yishen Qutong Simulant Granules
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Laercio Lopes DaSilvaDepartment of Medicine, MetroWest Medical Center/Tufts University School of Medicine, Framingham, Massachusetts.
Pedro Nazareth AguiarInstituto Oncoclinicas, São Paulo, Brazil.
Gilberto de Lima LopesDepartment of Medicine, Jackson Memorial Hospital/University of Miami, Miami, Florida.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaCombined Modality TherapyHumansImmunologic FactorsImmunotherapyImmunologic Factors

Identifiers

PMID34519775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.